{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-013248","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2021-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.697990+00:00","generated_at":"2026-06-28T20:16:05.257773+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Director Rajeev Shah resigns; C. Daniel Myers appointed to board","bullets":["Rajeev Shah resigned effective Oct 15, 2021; no disagreement with company on operations.","C. Daniel Myers appointed as Class III director, term expiring at 2023 annual meeting.","Myers is CEO of MediPrint Ophthalmics, former CEO and co-founder of Alimera Sciences.","Myers received option to purchase 42,000 shares at $2.21, vesting over three years.","Myers also appointed to Compensation Committee and Nominating and Corporate Governance Committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-013248","json":"https://secwatch.observer/filing/0001558370-21-013248.json","markdown":"https://secwatch.observer/filing/0001558370-21-013248.md","text":"https://secwatch.observer/filing/0001558370-21-013248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021013248/0001558370-21-013248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021013248/kala-20211014x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:16:05.257773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e6d83ffe5","claim":"Rajeev Shah resigned as member of the Board of Directors at KALA BIO, Inc..","evidence_excerpt":"On October 14, 2021, Rajeev Shah notified Kala Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), which resignation was effective on October 15, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021013248/0001558370-21-013248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"1822efd8f1","claim":"C. Daniel Myers was appointed as member of the Board of Directors at KALA BIO, Inc..","evidence_excerpt":"On October 15, 2021, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed C. Daniel Myers as a member of the Board, effective immediately, to fill the vacancy created by the resignation of Mr. Shah.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837021013248/0001558370-21-013248-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}